De novo donor HLAspecific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation 
De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation Although pre-transplant human leukocyte antigen (HLA) donor-specific antibodies (DSA) are known to be associated with poor graft survival early after solid-organ transplantation, [2] [3] [4] there is little evidence implicating posttransplant DSA in the development of bronchiolitis obliterans syndrome (BOS) in the long term after lung transplantation. Several studies have suggested an association between HLA antibodies detected post-transplant and acute rejection and BOS. [5] [6] [7] [8] Girnita et al showed an association between development of HLA antibodies and acute rejection 5 and BOS 6 in a small series of lung transplants. However, their analysis was not time-dependent and did not account for time to BOS. Studies have been limited by relatively small numbers and methods of antibody detection, and have not always considered whether the antibodies were donor-directed. Recently, Hachem et al 9 showed an indirect link between DSA and development of BOS. Patients with de novo DSA were treated with either intravenous immunoglobulin (IVIg) and rituximab or IVIg alone. Patients with successful depletion of DSA had greater freedom from BOS and improved survival, suggesting that DSA are involved in the development of BOS. In both renal and cardiac transplantation there is evidence that development of HLA-specific antibodies, particularly if donorspecific, are associated with poor graft survival. [10] [11] [12] The development of BOS is the major cause of death beyond the first year after lung transplantation. 1, 13 BOS is defined according to loss of lung function (forced expiratory volume in 1 second [FEV 1 ]) in proportion to maximal baseline value obtained post-transplantation in the absence of known acute causes of declining FEV 1 , such as acute rejection and infection. 14 There are three stages of BOS, categorized by the severity of the decrease in FEV 1 from baseline. BOS has a significant negative impact on patient survival; there is a 3-fold increase in the risk of death at each stage of the disease, irrespective of whether it develops early or late. 14 The objective of this study was to ascertain the frequency of HLA-specific antibodies produced after transplantation and to determine whether the development of de novo DSA is an independent predictor of development of BOS or patient survival.
Methods Patients
In this single-center study we assessed adult patients undergoing lung transplantation between January 2003 and December 2009. Only patients without DSA prior to transplantation were included.
Between January 2003 and December 2009, 188 adults underwent lung transplantation. Five of these patients were excluded because they had DSA before transplantation. The mean follow-up was 3.55 years. There were 98 (54%) male and 85 (46%) female patients, with a mean age 45.3 Ϯ 12.7 years. The underlying lung pathology was as follows: chronic obstructive pulmonary disease in 75 (41%); pulmonary fibrosis in 22 (12%); cystic fibrosis in 60 (32%); pulmonary hypertension in 5 (3%); and 21 (12%) with other diagnoses (Table 1 ). The mean number of HLA mismatches was 1.34 Ϯ 0.68 for HLA-A, 1.56 Ϯ 0.54 for HLA-B, 1.49 Ϯ 0.60 for HLA-DR and 1.22 Ϯ 0.59 for HLA-DQ. All recipients and their donors were HLA typed for HLA-A, -B, -C, -DR and -DQB by polymerase chain reaction-sequence-specific primer (PCR-SSP) at the time of, or before, transplantation. In addition, recipients were typed for HLA-DQA, -DPA or -DPB if found to have produced antibodies to any antigens of these loci. All patients included in the study were transplanted with a negative cytotoxic donor lymphocyte crossmatch.
No patient received induction immunosuppression. Maintenance immunosuppression consisted of steroids, cyclosporine and azathioprine. Changes in immunosuppressant therapy were documented during the follow-up period and are included in the statistical analysis. Patients who developed HLA-specific antibodies during their routine monitoring were prescribed mycophenolate mofetil (MMF) in place of the azathioprine treatment. Those who then developed allograft dysfunction were investigated to exclude acute cellular rejection, lymphocytic bronchiolitis/neutrophilic reversible allograft dysfunction, gastroesophageal reflux or airway injury due to infection/colonization. Any anastomotic stenosis was treated before establishing a diagnosis of BOS. These entities were treated appropriately, but due to uncertainty regarding positively identifying antibody-mediated lung injury and the potential side effects of any treatment, only patients with a rapid decline in lung function were actively treated. In this cohort 2 of the 38 patients who developed DSA showed a rapid decline in lung function and were treated with immunoadsorption to remove HLAspecific antibodies. All patients received ongoing Pneumocystitis pneumonia (PCP) prophylaxis with cotrimoxazole and 3 months of cytomegalovirus (CMV) prophylaxis with valganciclovir. Those with fungal colonization or history of fungal infection before transplant received voriconazole for 6 weeks with monitoring of blood levels. Routine peri-operative antibiotic prophylaxis was given according to laboratory sensitivities for those with long-term bacterial colonization and with piperacillin/tazobactam and teicoplanin for those without previous colonization.
HLA antibody screening
In total, 1,696 sera from 148 patients were tested for the presence of HLA antibodies (mean 11.46 Ϯ 6.86 samples per patient) using samples collected at clinic visits and additional samples collected at times of clinical deterioration. HLA antibody detection was performed by adding 20 ml of patient serum to 2.5 ml of HLAcoated microbeads for 30 minutes using a mixed assay (LABScreen; One Lambda, Inc., Canoga Park, CA). After washing, the beads were incubated for 30 minutes with 50 ml of anti-human IgG-phycoerythrin-conjugated monoclonal antibody. Results were recorded according to mean fluorescence intensity (MFI) of staining with positive values assigned using pre-determined cutoff values. Each new lot of LABScreen mixed beads undergoes a rigorous validation procedure before introduction into the laboratory. A panel of at least 100 sera previously tested by singleantigen beads, containing both negative serum and positive serum with reactivity for HLA-A, -B, -C, -DR, -DQA, -DQB and -DPB alleles with varying MFI levels (ranging from $500 to 20,000), was used. Receiver operating characteristic analysis was performed to determine cut-offs enabling detection of 499% of HLA antibodies.
Sera found to potentially contain HLA-specific antibodies were further tested using LABScreen single-antigen kits (One Lambda, Inc.). Ten microliters of serum was incubated with 2.5 ml of HLAcoated microbeads. No pre-determined cut-off MFI value was used to assign positivity. Definition of antibody specificity was determined using pattern of reactivity, self-antigens and cross-reactive groups. Donor-specific reactivity was assigned using results from the singleantigen analysis. The cumulative DSA MFI (cMFI) was calculated as the sum of MFIs for each of the individual DSA detected. percent of maximum post-transplant FEV 1 . BOS Stage 1 (BOS1) is classified as 66% to 80% of baseline, BOS Stage 2 (BOS2) as 51% to 65% of baseline and BOS Stage 3 (BOS3) as o50% of the baseline. The protocol excludes acute cellular rejection and infection as causes of transient fall in lung function and includes screening for gastroesophageal reflux disease, performing Nissen fundoplication when appropriate, and later treatment of lymphocytic bronchiolitis with azithromycin. Episodes of infection were defined as those requiring hospital admission for administration of anti-bacterial drugs or supportive treatment for viral lower respiratory tract infection, or any prescription for anti-fungal medication. Acute cellular rejection underlying acute deterioration was excluded by transbronchial biopsy and, when present, was treated with high-dose intravenous methylprednisolone.
Uni-and multivariable analyses of risk factors
Univariable analysis included a number of clinical parameters. The time-independent variables included were: recipient age at transplant, recipient gender and underlying lung pathology; donor age, donor gender and cause of death; transplant type; ischemic time; donor and recipient CMV status; primary graft dysfunction (PGD); and HLA mismatch at time of transplant. Time-dependent variables included: de novo DSA; persistent de novo DSA (defined as continued production of DSA for 46 months); infection (bacterial, fungal and viral); CMV antigenemia; acute cellular rejection (clinical or histologic); and changes in immunosuppressant therapy. Acute cellular rejection was defined as clinical when treated with intravenous methylprednisone or as histologic using ISHLT-defined criteria. Infection has been defined as an infective episode requiring inpatient anti-microbial therapy, with persistent infection defined as the repeated need for anti-microbial therapy. The time to the second episode of treated infection was used as the time to recurrent or persistent infection for analysis. Multivariable analysis was performed to determine whether any variables were independent predictors of poor patient survival or development of BOS. Variables included in this analysis were those that showed trends in the univariable analysis (i.e., p o 0.10).
Statistical analysis
Cox proportional hazards analysis was used for uni-and multivariable analyses for both patient survival and time to development of BOS. The occurrence of de novo DSA was modeled as a time-dependent variable, taking the value 0 until first occurrence and 1 thereafter; persistent DSA was considered to have occurred following two consecutive positives, at least 6 months apart. p o 0.05 was considered statistically significant.
Multivariable analysis was used to determine whether any of the potential confounding variables were independent predictors of poor patient survival or development of BOS (Stages 1, 2 or 3). Variables included in these analyses were those that showed trends in univariable analysis (i.e., p o 0.1). Variables found not to be independently predictive of survival or development of BOS were dropped using the backward elimination procedure.
Theoretical survival curves based on the fitted Cox model for the time-dependent variable of de novo DSA were constructed for time to BOS1, BOS2, BOS3 and patient survival. The plots comprise fitted survival curves from the fitted Cox model for a theoretical patient never producing DSA after transplant and a patient producing DSA immediately after transplant is performed.
Results

Post-transplant HLA antibodies
Thirty-five patients died shortly after transplant with no HLA antibody testing. HLA antibody data were therefore available for 148 patients; 66 (45%) were found to have produced HLA-specific antibodies after transplant. Of these, 38 (26%) had produced antibodies to donor HLA antigens and 28 (19%) had non-donor-specific HLA antibodies. DSA were first detected between 14 and 2,225 (mean 497.8 Ϯ 645) days after transplant.
Of those with DSA, 10 (26%) had antibodies directed against donor HLA Class I antigens, 26 (69%) had antibodies directed against donor HLA Class II antigens, and 2 (5%) had antibodies directed against both HLA Class I and II donor antigens. In 25 (89%) of the 28 patients with Class II directed DSA, the antibodies were directed against donor HLA-DQ specificities.
There was an increased frequency of sensitized patients with non-donor-specific (NDS) antibodies before transplant in the de novo DSA group. Patients in the de novo DSA group had a lower mean age at transplant, longer ischemic time and increased frequency of double lung transplants. There were no observed differences in HLA mismatching between donor and recipient ( 
Post-transplant de novo DSA and patient survival
In the univariable analysis, there was evidence of reduced patient survival after the first occurrence of de novo DSA (HR ¼ 1.886, p ¼ 0.047) ( Table 3 ). Figure 2 demonstrates the predicted survival curve for time to death for de novo DSA from the fitted Cox model for patients producing DSA at the outset and patients with no detectable DSA at any time-point after lung transplantation. De novo DSA with cMFI 410,000 was also strongly associated with poor patient survival (HR ¼ 2.404, p ¼ 0.0450), as was persistent de novo DSA with cMFI 410,000 (HR ¼ Table 2 ).
In addition to de novo DSA there were also significant associations with shorter time to BOS2 for original diagnosis of emphysema (HR ¼ 
Discussion
This study has shown that de novo production of DSA after lung transplantation is an independent risk factor for the development of BOS and poor patient survival.
Solid-phase assays, particularly Luminex-based assays, can detect HLA antibodies in more patients than was previously possible. It is likely that patients will produce de novo DSA after transplantation and it is important to understand the clinical relevance and long-term effects of DSA after lung transplantation. In this study patients found to have pre-formed DSA before transplantation were excluded to determine the effects of de novo DSA on outcomes after lung transplantation.
Patients were routinely monitored for HLA antibody production after transplant. Of the 148 lung transplant recipients who had survived 490 days, and when posttransplant sera were available, 38 had produced de novo DSA after transplant and 28 had non-donor-specific HLA antibodies. Both de novo DSA and persistent DSA were found to be associated with development of BOS and poor patient survival in univariable analyses. In multivariable analyses, de novo DSA was found to be an independent predictor for development of BOS1, BOS2 and BOS3, as well as being an independent predictor for poor patient survival. These findings are similar to those seen in both renal 10, 16 and cardiac 12, 17 transplant studies. In a large study of renal allografts, Lachmann et al showed that DSA detected post-transplant using Luminex single-antigen bead assays were associated with significantly reduced graft survival, 10 whereas we previously found de novo DSA after cardiac transplantation to be an independent predictor of poor patient survival. 12 As with other studies 12, 18, 19 the majority of DSA detected in this study were directed against HLA Class II antigens, particularly HLA-DQ. Of the 28 patients with Class II directed DSA, 25 (89%) were found to be directed against donor HLA-DQ specificities. HLA Class II molecules are normally expressed on lung tissue, and are upregulated in patients with obliterative bronchiolitis after lung transplantation. 20, 21 Increasing HLA Class II mismatching correlated with increased frequency and earlier development of DSA directed against Class II donor antigens (data not shown); however, there was no correlation between PGD and subsequent development of DSA. . In all panels, the two curves represent predictions corresponding to a patient never having DSA and a patient first having DSA immediately after lung transplantation. Previous studies suggested a role for HLA antibodies after lung transplantation. [5] [6] [7] [8] 22, 23 Girnita et al found that HLA antibodies are associated with increased frequency and more severe acute rejections after lung transplant, 5 as well as increased incidence of BOS. 6 Their studies had small patient cohorts and, although they used solid-phase antibody assays for HLA antibody detection, they were enzyme-linked immunoassay (ELISA)-based and, as such, probably underestimated the level of HLA antibody production. Other early studies 8, 23 utilized complement-dependent cytotoxicity assays for antibody detection and did not assign donor reactivity to the antibodies detected. A recent study by Hachem et al 9 provided indirect evidence of a role for de novo DSA in the development of BOS after lung transplantation. Their lung transplant recipients found to have produced de novo DSA were treated with IVIg alone or in combination with rituximab to reduce antibody levels. For patients in whom DSA was depleted, there was a lower incidence of BOS and improved survival. Not all HLA antibodies are persistent after transplant. A proportion of patients in our study only produced DSA at one time-point and had become negative at the next visit. Therefore, it is possible that those patients who responded to treatment in the Hachem et al study would have returned to an antibody-negative state without intervention.
A recent study by Snyder et al 24 showed that de novo production of HLA antibodies was associated with development of BOS and poor survival, whereas DSA were only found to be predictive of poor survival. In our study we found DSA to be an independent predictor of development of BOS and poor survival. One possible explanation for this could be that different parameters were used for the interpretation of HLA antibody assays. Whereas Snyder et al used an MFI cut-off of 1,000 to define HLA antibodies, we used several parameters, such as pattern of reactivity, self-antigens and cross-reactive groups, with no pre-defined cut-off. Furthermore, we analyzed the data with respect to the different stages of BOS and found stronger associations with increasing stages of the disease, whereas Snyder et al did not analyze BOS severity. Interestingly, we observed stronger associations with development of BOS and patient survival with de novo DSA where the cumulative MFI levels were in excess of 10,000, suggesting that stronger responses are associated with poor outcomes. However, there are many characteristics of DSA that could influence outcomes, including titer, complement fixation and cryptic epitopes, among others, and these need to be fully investigated.
BOS is multifactorial in etiology with a number of factors suggested to predispose to development, including both immunologic and non-immunologic factors. Immunologic factors suggested to have a role in the development of BOS include acute rejection, 25, 26 lymphocytic bronchitis, 27, 28 HLA mismatch [29] [30] [31] and CMV pneumonitis, 8, [32] [33] [34] and non-immunologic factors include ischemia, 30 donor age 35 and recipient age. 36 In the present study we found that infections, an indication for transplant of emphysema, and female recipient status were also independent predictors of earlier development of BOS2, whereas female recipient status was associated with earlier onset of BOS3. It is possible that female recipients are more likely to develop BOS as a result of alloimmune reactivity due to anamnestic responses to previous sensitizing events such as pregnancy, although in this study we did not observe an increased Predicted survival curves based on the fitted Cox model with the time-dependent variable de novo DSA demonstrates decreased time to patient death for DSA; the two curves represent predictions corresponding to a patient never having DSA and a patient first having DSA immediately after lung transplantation. frequency of de novo DSA production. Furthermore, PGD, infection, persistent infections and pre-transplant diagnosis of emphysema and fibrosis were independent predictors (compared with cystic fibrosis) for poor patient survival. Although it is of interest that a primary indication for transplantation of emphysema was associated with development of BOS2 and BOS3 in multivariable analyses, this does not appear to have any clinical relevance and it is difficult to imagine a causative association. A number of studies have suggested possible mechanistic effects of HLA-specific antibodies in the development of obstructive airway disease. [37] [38] [39] [40] [41] The majority of these studies utilized W6/32, a monoclonal antibody directed against a monomorphic determinant on HLA Class I molecules. Ligation of W6/32 to epithelial cells has been shown to cause cell proliferation, production of growth factors and chemotactic factors, as well as cell death through apoptosis. However, the majority of DSA detected after lung transplantation are directed against HLA Class II molecules. A recent study by Takenaka et al 41 demonstrated that administration of a monoclonal antibody to Class II antigens led to the development of obstructive airway disease in a mouse model. Further work is required to understand the effects of antibodies to Class II antigens on epithelial cells and development of BOS.
Limitations of our investigation are that it was a singlecenter retrospective study and there was a relatively small number of DSA-positive patients. It would be necessary to confirm these findings with other studies at other centers or in multicenter studies. Another limitation is the lack of complete information regarding histologically defined acute rejection. At our institution, routine monitoring by transbronchial biopsy is not undertaken, so diagnosis of acute rejection may be underestimated. Furthermore, since this series of patients were transplanted, the maintenance immunosuppression regimen has changed. All patients now receive a combination of tacrolimus and MMF. It has been reported that MMF inhibits antibody production, 42, 43 and it is possible that the immunosuppression regimen currently used may result in fewer DSApositive patients after transplantation. Clearly, minimizing HLA mismatches between donors and recipients would also be likely to result in a decreased frequency of DSA production after transplantation, but this is not logistically possible at the present time.
In conclusion, de novo DSA produced after lung transplantation have a significantly detrimental impact on development of BOS and patient survival. Regular post-transplant monitoring for DSA should be implemented starting early after transplantation. Although the results of our study suggest that treatment options to limit antibody-mediated damage and antibody-removal therapies may be considered when DSA are first detected, the published supporting evidence for this remains weak and a randomized, controlled trial of treatment options would establish a clearer understanding of the benefits, if any, of antibody-removal therapies.
